PHENYLARTHRITE SOLUTION FOR INJECTION

国家: 爱尔兰

语言: 英文

来源: HPRA (Health Products Regulatory Authority)

有效成分:

PHENYLBUTAZONE

可用日期:

Vetoquinol Ireland Limited

ATC代码:

QM01AA01

INN（国际名称）:

PHENYLBUTAZONE

剂量:

20 %w/v

药物剂型:

Solution for Injection

处方类型:

POM

治疗组:

Canine, Equine Non Food

治疗领域:

Phenylbutazone

疗效迹象:

N.S.A.I.D

授权状态:

Authorised

授权日期:

1989-10-01

产品特点

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Phenylarthrite solution for injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Solution for injection.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs
Horses declared as not being intended for slaughter for human consumption.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of arthritis, tendinitis, muscular and articular rheumatisms, congestive processes, hyperthermia,
heatstroke, inflammatory complications of various traumatic or bacterial infections. (With approved antibiotic if
necessary).
4.3 CONTRAINDICATIONS
Do not use in treatment of animals suffering from cardiac, hepatic and renal deficiencies.
Do not use in cats.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not administer other non-steroidal anti-inflammatory drugs concurrently or within 24 hours of each other.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
The intravenous injections should be done slowly. In case of intravenous injection, avoid mixing blood and product in
the syringe.
Intramuscular injections should be done deeply in the muscular tissues.
In all cases the injections should be performed under rigorous asepsis
Active substance
Phenylbutazone 20 % w/v
Excipient
Benzyl Alcohol
1 % w/v
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 13/10/2015_
_CRN 7022044_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use in very young or old animals may involve additional risk. If such use cannot be avoided, animals require careful
clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive animals as the